Ustekinumab is NOT Recommended for Axial Spondyloarthritis
Ustekinumab should not be used for axial spondyloarthritis, even in patients who have failed NSAIDs and TNF inhibitors, as it has failed to demonstrate efficacy in multiple randomized controlled trials and is not included in current treatment guidelines for this indication.
Evidence Against Ustekinumab in Axial SpA
The most definitive evidence comes from three multicenter, randomized, double-blind, placebo-controlled trials that conclusively demonstrated ustekinumab failed to show efficacy in axial spondyloarthritis 1. These trials included:
- Study 1: Anti-TNF-naïve patients with radiographic axial SpA
- Study 2: Patients with inadequate response or intolerance to anti-TNF
- Study 3: Patients with nonradiographic axial SpA
Neither the 45 mg nor 90 mg dose demonstrated clinically meaningful improvement over placebo on any key efficacy endpoints, leading to premature discontinuation of all three studies 1.
Guideline-Based Treatment Algorithm
Current ASAS-EULAR and PANLAR guidelines provide clear direction for TNF-inhibitor failures 2, 3:
For Patients Failing First TNF Inhibitor:
Primary recommendation: Switch to either:
- IL-17 inhibitor (secukinumab or ixekizumab), OR
- Different TNF inhibitor, OR
- JAK inhibitor (tofacitinib or upadacitinib)
The 2023 PANLAR guidelines specifically recommend switching to a bDMARD with a different mechanism of action after primary TNF inhibitor failure 2. The 2022 ASAS-EULAR update confirms TNF inhibitors and IL-17 inhibitors as the established biologic options, with JAK inhibitors as targeted synthetic DMARDs 3.
Eligibility Criteria for Advanced Therapy:
- ASDAS ≥2.1
- Failed ≥2 NSAIDs at maximum tolerated doses
- Plus at least one of:
- Elevated CRP
- MRI inflammation of sacroiliac joints
- Radiographic sacroiliitis
Why the Discrepancy with Early Data?
An early 2014 open-label, proof-of-concept study suggested potential benefit, with 65% of patients achieving ASAS40 response 4. However, this was a small (n=20), uncontrolled, open-label study—a study design highly susceptible to placebo effect and bias. The subsequent large, rigorous, placebo-controlled trials definitively refuted these findings 1.
FDA-Approved Indications for Ustekinumab
The FDA label for ustekinumab (Stelara) includes 5:
- Plaque psoriasis
- Psoriatic arthritis
- Crohn's disease
- Ulcerative colitis
Axial spondyloarthritis is notably absent from approved indications, reflecting the failed clinical trial program.
Special Considerations for Comorbidities
If your patient has coexistent inflammatory bowel disease, monoclonal antibody TNF inhibitors (infliximab, adalimumab, golimumab) are strongly preferred over IL-17 inhibitors, which should be avoided in active IBD 2. While ustekinumab is effective for IBD, this does not translate to axial disease efficacy.
For recurrent uveitis, monoclonal antibody TNF inhibitors are conditionally recommended over other biologics 2.
For significant psoriasis, IL-17 inhibitors are preferred 3.
Clinical Pitfalls to Avoid
- Do not extrapolate ustekinumab's efficacy in psoriatic arthritis to axial spondyloarthritis—these are distinct disease processes with different pathophysiology
- Do not rely on the 2014 open-label study data when high-quality RCT data contradicts it
- Do not use ustekinumab off-label for axial SpA simply because other options have failed—the evidence shows it will not work
Bottom Line
Use evidence-based alternatives: IL-17 inhibitors (secukinumab, ixekizumab), a second TNF inhibitor, or JAK inhibitors (tofacitinib, upadacitinib) for patients failing initial TNF inhibitor therapy 2, 3. Ustekinumab has no role in axial spondyloarthritis management based on failed phase 3 trials and absence from all current treatment guidelines.